CD274 and head and neck squamous cell carcinoma: Immunotherapy agents such as programmed cell death 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) inhibitors show high efficacy and acceptable safety in HNSCC [8, 9].